20/04/2026
NeuralCIM® – New neuroprotective option for brain diseases
What is NeuralCIM® ?
NeuralCIM® is a novel neuroprotective drug designed to combat brain diseases, especially neurodegenerative diseases such as Alzheimer's disease.
In patients treated in clinical trials, NeuralCIM® has shown a 60 percent improvement in cognitive function, with a sustained effect lasting more than a year and good tolerability. This opens new therapeutic opportunities for a disease that currently lacks an effective treatment.
On July 28, 2025, CECMED, Cuba's drug regulatory agency, authorized the use of this drug, with registration number B-25-019-N07C, in patients with mild or moderate Alzheimer's disease.
Access to medication
For Cuban patients
Cuban patients who can benefit from NeuralCIM® are treated in specialized Neurology consultations of the National Health System.
It is the Neurology specialist who, in compliance clinical evaluation, determines if the medication is appropriate for each case and makes the prescription.
Overall demand for cuban domestic market and lts financing scheme is being defined by MINSAP, since the cuban health care is free for patients.
For foreign patients
Patients interested in NeuralCIM® can access it through the international services enabled in Cuba, which provide specialized advice, personalized clinical evaluation and indicate the treatment according to the specific medical requirements. The reference institutions you can contact are:
La Pradera International Health Center.
Email addresses: relaciones@cislapradera.cu ; eventos@cislapradera.cu ; comercial@cislapradera.cu ; lapraderacomercial24@gmail.com
Telephone: +53 7272-52-73
International Center for Neurological Restoration, CIREN
Email : centraldeventasciren@neuro.ciren.cu Telephone: +53 7 2715823.
Frequently Asked Questions (FAQ)
1. Does the CIM directly serve patients?
No. The CIM does not have medical offices or offer medical care services.
2. Can I buy NeuralCIM® directly from the CIM?
No. Sales to patients are conducted exclusively through authorized healthcare institutions.
3. So, can the CIM help me get the medication?
CIM can guide and inform you about the product and redirect your interest towards the competent health institutions, but does not intervene in the evaluation, prescription or direct supply to the patient.
4. If I am a Cuban patient, what do I do?
You should schedule an appointment with your specialist neurologist within the National Health System. The neurologist will assess whether NeuralCIM® is appropriate for your case.
5. If I am a foreigner, where can I receive care?
La Pradera International Health Center and the International Center for Neurological Restoration (CIREN) are the authorized international clinics in Cuba. There you will receive the appropriate evaluation and treatment.
6. What is the safety level of the medication?
NeuralCIM® has an adequate safety profile. Most adverse effects are mild, reversible, and do not require discontinuation of treatment.
7. What are the most frequent adverse events?
Common side effects (may affect up to 1 in 10 people):
• Blood pressure (hypertension)
• Burning sensation in the nasal mucosa
• Nasal burning
• Headache
• Nausea
• Sneezing
Uncommon side effects (may affect up to 1 in 100 people):
• Nasal congestion
• Fever
• Fatigue (tiredness)
• Teary eyes
• Burning in the eyes
• Agitation
• Dizziness
• Sleepiness
• Elevated liver enzymes (detected in blood tests)
• Decreased hematocrit (detected in blood tests)
• Decreased platelets (detected in blood tests)
8. Are there other therapies available worldwide for this disease, and what are their most frequent adverse events?
Yes, there are other treatments available for this disease. Some are traditional medications, such as memantine and donepezil. There are also more advanced therapies, such as aducanumab , lecanemab, and donanemab , which attempt to slow the progression of the disease. However, these latter therapies have not proven very effective in delaying mental decline and, moreover, can cause serious side effects, such as inflammation and bleeding in the brain.